دورية أكاديمية
Amorphous Solid Dispersion as Drug Delivery Vehicles in Cancer.
| العنوان: | Amorphous Solid Dispersion as Drug Delivery Vehicles in Cancer. |
|---|---|
| المؤلفون: | Budiman A; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung-Sumedang Km. 21, Bandung 45363, Indonesia., Handini AL; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung-Sumedang Km. 21, Bandung 45363, Indonesia., Muslimah MN; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung-Sumedang Km. 21, Bandung 45363, Indonesia., Nurani NV; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung-Sumedang Km. 21, Bandung 45363, Indonesia., Laelasari E; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung-Sumedang Km. 21, Bandung 45363, Indonesia., Kurniawansyah IS; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung-Sumedang Km. 21, Bandung 45363, Indonesia., Aulifa DL; Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung-Sumedang Km. 21, Bandung 45363, Indonesia. |
| المصدر: | Polymers [Polymers (Basel)] 2023 Aug 11; Vol. 15 (16). Date of Electronic Publication: 2023 Aug 11. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101545357 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4360 (Electronic) Linking ISSN: 20734360 NLM ISO Abbreviation: Polymers (Basel) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel : MDPI |
| مستخلص: | Cancer treatment has improved over the past decades, but a major challenge lies in drug formulation, specifically for oral administration. Most anticancer drugs have poor water solubility which can affect their bioavailability. This causes suboptimal pharmacokinetic performance, resulting in limited efficacy and safety when administered orally. As a result, it is essential to develop a strategy to modify the solubility of anticancer drugs in oral formulations to improve their efficacy and safety. A promising approach that can be implemented is amorphous solid dispersion (ASD) which can enhance the aqueous solubility and bioavailability of poorly water-soluble drugs. The addition of a polymer can cause stability in the formulations and maintain a high supersaturation in bulk medium. Therefore, this study aimed to summarize and elucidate the mechanisms and impact of an amorphous solid dispersion system on cancer therapy. To gather relevant information, a comprehensive search was conducted using keywords such as "anticancer drug" and "amorphous solid dispersion" in the PubMed, Scopus, and Google Scholar databases. The review provides an overview and discussion of the issues related to the ASD system used to improve the bioavailability of anticancer drugs based on molecular pharmaceutics. A thorough understanding of anticancer drugs in this system at a molecular level is imperative for the rational design of the products. |
| References: | Adv Drug Deliv Rev. 2012 Apr;64(5):396-421. (PMID: 21843564) Int J Pharm. 2017 Mar 15;519(1-2):365-372. (PMID: 28131850) AAPS J. 2012 Sep;14(3):380-8. (PMID: 22434258) J Pharm Sci. 2013 Jan;102(1):171-84. (PMID: 23132686) J Pharm Sci. 2012 Sep;101(9):3456-64. (PMID: 22437488) Drug Deliv. 2020 Dec;27(1):110-127. (PMID: 31885288) Drug Deliv. 2020 Dec;27(1):309-322. (PMID: 32037895) Pharmaceutics. 2020 Jun 11;12(6):. (PMID: 32545270) Biomacromolecules. 2014 Feb 10;15(2):500-11. (PMID: 24328187) Int J Pharm. 2013 Feb 25;443(1-2):95-102. (PMID: 23299082) Int J Pharm. 2017 Aug 30;529(1-2):294-302. (PMID: 28689964) J Pharm Sci. 2018 Jan;107(1):170-182. (PMID: 29031953) Adv Drug Deliv Rev. 2016 May 1;100:85-101. (PMID: 26826438) Int J Pharm. 2008 Sep 1;361(1-2):12-8. (PMID: 18584979) Pharmaceutics. 2019 Jun 10;11(6):. (PMID: 31185610) Int J Pharm. 2020 Apr 15;579:119149. (PMID: 32070762) Mol Pharm. 2012 Mar 5;9(3):581-90. (PMID: 22280478) Pharm Dev Technol. 2016 Sep;21(6):737-48. (PMID: 26024240) Pharm Res. 2012 Mar;29(3):806-17. (PMID: 22009589) J Pharm Sci. 2009 Jun;98(6):2133-9. (PMID: 18837010) J Pharm Sci. 2011 Nov;100(11):4687-99. (PMID: 21681752) BMJ Open. 2017 Mar 13;7(3):e013053. (PMID: 28289045) J Control Release. 2018 Jun 10;279:114-125. (PMID: 29654798) Mol Oncol. 2012 Apr;6(2):155-76. (PMID: 22440008) Pharmaceutics. 2020 Sep 30;12(10):. (PMID: 33008124) Int J Pharm. 2021 Mar 15;597:120312. (PMID: 33540023) Int J Pharm. 2019 Mar 10;558:215-224. (PMID: 30654059) Eur J Pharm Sci. 2008 Oct 2;35(3):203-10. (PMID: 18656535) AAPS PharmSciTech. 2018 Jul;19(5):1933-1956. (PMID: 29846889) J Clin Oncol. 2010 Feb 20;28(6):1061-8. (PMID: 20100962) Int J Pharm. 2002 Jan 14;231(2):131-44. (PMID: 11755266) Int J Pharm. 2019 Oct 30;570:118661. (PMID: 31491482) J Pharm Sci. 2016 Mar;105(3):1113-23. (PMID: 26886329) Int J Pharm. 2020 Jan 25;574:118885. (PMID: 31765775) Eur J Pharm Biopharm. 2012 May;81(1):207-13. (PMID: 22293573) Int J Pharm. 2016 Sep 25;511(2):765-73. (PMID: 27480397) J Drug Deliv Sci Technol. 2020 Feb;55:. (PMID: 32863891) Int J Pharm. 2019 Oct 30;570:118683. (PMID: 31513869) Drug Dev Ind Pharm. 2011 Sep;37(9):1026-35. (PMID: 21417604) Eur J Pharm Sci. 2016 Dec 1;95:130-137. (PMID: 27167825) Lancet Oncol. 2016 Mar;17(3):367-377. (PMID: 26874901) J Adv Pharm Technol Res. 2016 Jul-Sep;7(3):105-9. (PMID: 27429930) Int J Pharm. 2017 Nov 30;533(2):470-479. (PMID: 28363855) J Med Chem. 2002 Jun 6;45(12):2615-23. (PMID: 12036371) Adv Drug Deliv Rev. 2016 May 1;100:51-66. (PMID: 26826439) Drug Discov Today. 2012 May;17(9-10):486-95. (PMID: 22138563) Eur J Pharm Sci. 2014 Oct 1;62:293-300. (PMID: 24953904) Mol Pharm. 2017 Jan 3;14(1):206-220. (PMID: 28043130) Adv Drug Deliv Rev. 2012 Apr;64(5):422-30. (PMID: 22178405) Mol Pharm. 2014 Jan 6;11(1):329-37. (PMID: 24256090) J Pharm Sci. 2019 Aug;108(8):2561-2569. (PMID: 30878513) Int J Pharm. 2018 Apr 5;540(1-2):106-119. (PMID: 29425762) Int J Pharm. 2007 Jul 18;339(1-2):3-18. (PMID: 17537600) J Pharm Sci. 2018 Mar;107(3):887-896. (PMID: 29133233) Int J Pharm. 2018 Jan 15;535(1-2):379-392. (PMID: 29128423) Blood. 2020 Jun 11;135(24):2137-2145. (PMID: 32219442) Drug Dev Ind Pharm. 2015;41(9):1401-15. (PMID: 25853292) Semin Oncol. 1993 Aug;20(4 Suppl 3):1-15. (PMID: 8102012) J Pharm Sci. 2017 Aug;106(8):1998-2008. (PMID: 28431965) J Pharm Sci. 2016 Sep;105(9):2527-2544. (PMID: 26886314) Mol Pharm. 2013 Oct 7;10(10):3665-75. (PMID: 23961978) Int J Pharm. 2017 Oct 5;531(1):313-323. (PMID: 28844901) Int J Pharm. 2000 Jan 5;193(2):247-59. (PMID: 10606789) J Pharm Sci. 1999 Oct;88(10):1058-66. (PMID: 10514356) AAPS PharmSciTech. 2016 Feb;17(1):43-55. (PMID: 26307759) Int J Pharm. 2015 Mar 15;481(1-2):114-24. (PMID: 25592956) Eur J Pharm Biopharm. 2010 Feb;74(2):340-51. (PMID: 19818402) Lancet. 2015 Aug 1;386(9992):444-51. (PMID: 26037941) Drug Discov Today. 2017 Dec;22(12):1835-1843. (PMID: 28893511) Int J Pharm. 1999 Apr 30;181(2):143-51. (PMID: 10370210) Lancet. 2013 Jan 26;381(9863):303-12. (PMID: 23177514) Oncologist. 2012;17(9):1204-12. (PMID: 22752067) Mol Pharm. 2015 Sep 8;12(9):3339-50. (PMID: 26070543) Eur J Pharm Sci. 2014 Aug 18;60:64-71. (PMID: 24832964) J Pharm Sci. 2015 Sep;104(9):2905-12. (PMID: 25740567) Int J Pharm. 2010 Jan 4;383(1-2):18-23. (PMID: 19732816) J Pharm Sci. 2014 Sep;103(9):2635-2662. (PMID: 24715618) Colloids Surf B Biointerfaces. 2015 Oct 1;134:423-30. (PMID: 26222408) Int J Pharm. 2020 Aug 30;586:119560. (PMID: 32565285) J Pharm Pharmacol. 2001 Mar;53(3):303-15. (PMID: 11291745) Mater Sci Eng C Mater Biol Appl. 2019 Jul;100:247-259. (PMID: 30948059) Int J Pharm. 2013 Aug 30;453(1):253-84. (PMID: 22820134) Int J Pharm. 2011 Sep 30;417(1-2):112-9. (PMID: 21182911) Sci Rep. 2014 Jun 04;4:5160. (PMID: 24895028) Ann Oncol. 2019 Sep 1;30(9):1437-1447. (PMID: 31218365) Pharm Res. 2015 Jan;32(1):167-79. (PMID: 25074468) Int J Pharm. 2019 Apr 20;561:82-92. (PMID: 30822504) Int J Pharm. 2018 May 5;542(1-2):18-26. (PMID: 29481948) Int J Pharm. 2015 Apr 10;483(1-2):256-67. (PMID: 25686660) Eur J Pharm Sci. 2015 Jul 10;74:11-7. (PMID: 25861719) Eur J Pharm Biopharm. 2010 Oct;76(2):311-9. (PMID: 20561585) J Pharm Sci. 2017 Oct;106(10):3150-3155. (PMID: 28625724) Mol Pharm. 2015 May 4;12(5):1477-84. (PMID: 25894099) Int J Pharm. 2012 Nov 15;438(1-2):11-9. (PMID: 22960321) Ther Deliv. 2015 Feb;6(2):247-61. (PMID: 25690090) Eur J Pharm Biopharm. 2013 Jan;83(1):87-94. (PMID: 23085332) Eur J Pharm Biopharm. 2021 Jan;158:132-142. (PMID: 33212185) Eur J Pharm Sci. 2013 Sep 27;50(1):8-16. (PMID: 23583787) Int J Pharm. 2012 Jan 17;422(1-2):202-10. (PMID: 22085435) Pharmaceutics. 2019 Mar 19;11(3):. (PMID: 30893899) Chem Pharm Bull (Tokyo). 2016 Dec 1;64(12):1739-1746. (PMID: 27733735) Eur J Pharm Biopharm. 2019 Feb;135:1-12. (PMID: 30529295) Mol Pharm. 2013 Nov 4;10(11):4330-46. (PMID: 24066837) Adv Drug Deliv Rev. 2012 Apr;64(5):440-8. (PMID: 22192684) Eur J Pharm Biopharm. 2015 Oct;96:237-46. (PMID: 26247119) Blood. 2011 Jan 27;117(4):1141-5. (PMID: 21098399) J Pharm Pharmacol. 2009 Dec;61(12):1571-86. (PMID: 19958579) N Engl J Med. 2015 Jan 1;372(1):30-9. (PMID: 25399551) Eur J Pharm Biopharm. 2000 Jul;50(1):47-60. (PMID: 10840192) J Pharm Sci. 1967 Oct;56(10):1238-42. (PMID: 6059440) AAPS PharmSciTech. 2015 Oct;16(5):1190-202. (PMID: 25732372) Int J Pharm. 2011 Apr 4;407(1-2):111-8. (PMID: 21277962) Int J Pharm. 2013 Jan 30;441(1-2):424-32. (PMID: 23174408) Lancet. 2017 Mar 4;389(10072):917-929. (PMID: 28126333) Int J Pharm. 2009 Oct 1;380(1-2):170-3. (PMID: 19596429) PLoS One. 2012;7(8):e42875. (PMID: 22912756) Int J Pharm. 2014 Jul 20;469(1):159-67. (PMID: 24751346) J Pharm Sci. 2009 Dec;98(12):4724-37. (PMID: 19455622) J Pharm Sci. 2013 Mar;102(3):967-81. (PMID: 23280631) Pharmaceutics. 2019 May 01;11(5):. (PMID: 31052438) Int J Pharm. 2013 Aug 30;453(1):65-79. (PMID: 22569230) AAPS PharmSciTech. 2016 Feb;17(1):120-32. (PMID: 26729526) Pharmaceutics. 2022 Aug 22;14(8):. (PMID: 36015373) Int J Pharm. 2019 Jan 10;554:302-311. (PMID: 30395959) J Pharm Sci. 2010 Sep;99(9):3901-22. (PMID: 20602348) Carbohydr Polym. 2013 Oct 15;98(1):659-64. (PMID: 23987396) Adv Drug Deliv Rev. 2007 Dec 10;59(14):1474-9. (PMID: 17928094) AAPS PharmSciTech. 2013 Mar;14(1):464-74. (PMID: 23389838) J Pharm Sci. 2020 Feb;109(2):1050-1058. (PMID: 31622601) Int J Pharm. 2019 May 1;562:113-123. (PMID: 30902705) Int J Pharm. 2010 Jan 15;384(1-2):93-9. (PMID: 19819314) Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):799-813. (PMID: 24056053) Pharm Res. 2013 Feb;30(2):502-11. (PMID: 23104579) Eur J Pharm Sci. 2020 Apr 15;146:105276. (PMID: 32092362) J Pharm (Cairo). 2014;2014:105382. (PMID: 26556187) Pharm Res. 2012 Oct;29(10):2777-91. (PMID: 22219167) Mol Pharm. 2012 Oct 1;9(10):2924-32. (PMID: 22905779) Drug Dev Ind Pharm. 2017 Nov;43(11):1817-1826. (PMID: 28665158) J Clin Oncol. 2019 Jun 1;37(16):1370-1379. (PMID: 30892989) J Control Release. 2018 Dec 28;292:172-182. (PMID: 30408553) J Control Release. 2009 Aug 19;138(1):16-23. (PMID: 19376169) J Control Release. 2019 Mar 28;298:68-82. (PMID: 30731151) Int J Pharm. 2015 Mar 1;480(1-2):137-42. (PMID: 25596415) Mol Pharm. 2015 Feb 2;12(2):576-89. (PMID: 25535667) Drug Des Devel Ther. 2015 Aug 04;9:4269-77. (PMID: 26345723) Int J Pharm. 2010 May 31;391(1-2):125-36. (PMID: 20211717) Acta Pharm Sin B. 2021 Aug;11(8):2505-2536. (PMID: 34522596) J Pharm Biomed Anal. 2014 Aug 5;96:10-20. (PMID: 24705456) Eur J Pharm Biopharm. 2015 Oct;96:32-43. (PMID: 26092472) J Phys Chem B. 2013 Feb 7;117(5):1494-500. (PMID: 23320811) Eur J Pharm Biopharm. 2016 Apr;101:145-51. (PMID: 26899127) Eur J Pharm Sci. 2019 Jan 15;127:199-207. (PMID: 30408522) Pharm Dev Technol. 2008;13(6):495-504. (PMID: 18720246) J Pharm Sci. 2009 Apr;98(4):1476-86. (PMID: 18752290) Adv Drug Deliv Rev. 2007 Jul 30;59(7):617-30. (PMID: 17597252) AAPS PharmSciTech. 2013 Jun;14(2):541-50. (PMID: 23430728) J Phys Chem B. 2015 Apr 9;119(14):4873-80. (PMID: 25781503) J Pharm Sci. 2004 Jan;93(1):124-31. (PMID: 14648642) Eur J Pharm Sci. 2021 Nov 1;166:105931. (PMID: 34256100) Int J Pharm. 2018 Oct 25;550(1-2):130-139. (PMID: 30130607) Adv Drug Deliv Rev. 2001 May 16;48(1):43-65. (PMID: 11325476) ACS Biomater Sci Eng. 2017 Oct 9;3(10):2399-2409. (PMID: 33445298) J Pharm Sci. 1969 May;58(5):538-49. (PMID: 5796439) CA Cancer J Clin. 2015 Mar;65(2):87-108. (PMID: 25651787) Mol Pharm. 2008 Nov-Dec;5(6):981-93. (PMID: 19434920) Pharmaceutics. 2020 Apr 09;12(4):. (PMID: 32283725) Acta Biomater. 2013 Nov;9(11):9086-97. (PMID: 23816652) Eur J Pharm Sci. 2015 Apr 25;71:12-24. (PMID: 25686597) Drug Des Devel Ther. 2020 Jul 27;14:2959-2975. (PMID: 32801637) AAPS PharmSciTech. 2016 Feb;17(1):20-42. (PMID: 26159653) Int J Pharm. 2019 Jan 30;555:394-403. (PMID: 30513399) Int J Pharm. 2019 Jun 10;564:162-170. (PMID: 30991134) Lancet. 2011 Dec 3;378(9807):1931-9. (PMID: 22056247) Polymers (Basel). 2022 Jan 26;14(3):. (PMID: 35160485) Mol Pharm. 2015 Apr 6;12(4):1180-92. (PMID: 25692314) J Control Release. 2015 Aug 10;211:85-93. (PMID: 26054795) Mol Pharm. 2017 Dec 4;14(12):4374-4386. (PMID: 29050468) Int J Pharm. 2020 Jan 25;574:118891. (PMID: 31786357) AAPS PharmSciTech. 2011 Dec;12(4):1209-19. (PMID: 21927960) Drug Discov Today Technol. 2012 Summer;9(2):e71-e174. (PMID: 24064267) Drug Des Devel Ther. 2015 May 28;9:2801-10. (PMID: 26060397) N Engl J Med. 2012 Nov;367(18):1694-703. (PMID: 23020132) Drug Dev Ind Pharm. 2015 Mar;41(3):382-97. (PMID: 24329130) Eur J Pharm Biopharm. 2015 Jan;89:329-38. (PMID: 25542681) Int J Pharm. 2015 Aug 1;491(1-2):208-17. (PMID: 26070248) J Clin Oncol. 1990 Jul;8(7):1263-8. (PMID: 1972736) N Engl J Med. 2017 Jul 27;377(4):352-360. (PMID: 28578607) Pharmaceutics. 2018 Jul 11;10(3):. (PMID: 29997332) Ther Deliv. 2015 Mar;6(3):339-52. (PMID: 25853309) J Pharm Sci. 2008 Sep;97(9):3830-41. (PMID: 18200526) Eur J Pharm Biopharm. 2022 Nov;180:170-180. (PMID: 36191869) Int J Pharm. 2011 Jun 15;411(1-2):172-7. (PMID: 21511016) Int J Pharm. 2000 Oct 10;207(1-2):49-56. (PMID: 11036229) Clin Cancer Res. 2016 Jan 1;22(1):44-53. (PMID: 26311725) Asian J Pharm Sci. 2017 Jan;12(1):66-72. (PMID: 32104315) Pharm Res. 2011 Oct;28(10):2353-78. (PMID: 21553168) N Engl J Med. 2017 Aug 3;377(5):454-464. (PMID: 28644114) Trends Pharmacol Sci. 2012 Apr;33(4):173-80. (PMID: 22410081) Drug Dev Ind Pharm. 2021 Jul;47(7):1011-1028. (PMID: 33818224) Cancer Treat Rev. 2016 Nov;50:247-263. (PMID: 27776286) |
| معلومات مُعتمدة: | no: 1834/UN6.3.1/PT.00/2023 the Ministry of Education, Culture, Research, and Technology of the Republic of Indonesia (KE-MENDIKBUDRISTEK, PDUPT) |
| فهرسة مساهمة: | Keywords: amorphous solid dispersion; bioavailability; dissolution; poorly water-soluble anticancer drugs |
| تواريخ الأحداث: | Date Created: 20230826 Latest Revision: 20230829 |
| رمز التحديث: | 20230830 |
| مُعرف محوري في PubMed: | PMC10457821 |
| DOI: | 10.3390/polym15163380 |
| PMID: | 37631436 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2073-4360 |
|---|---|
| DOI: | 10.3390/polym15163380 |